Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
Identifieur interne : 003E44 ( Main/Merge ); précédent : 003E43; suivant : 003E45Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
Auteurs : John G. Nutt [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2007-01.
English descriptors
- KwdEn :
- Animals, Dopamine (metabolism), Dopamine Agents (administration & dosage), Dopamine Agents (adverse effects), Dyskinesias (etiology), Dyskinesias (prevention & control), Humans, Levodopa (administration & dosage), Levodopa (adverse effects), Parkinson Disease (drug therapy), Pulse Therapy, Drug, continuous dopaminergic stimulation, levodopa, randomized clinical trials, sensitization, tolerance.
- MESH :
- chemical , administration & dosage : Dopamine Agents, Levodopa.
- chemical , adverse effects : Dopamine Agents, Levodopa.
- chemical , metabolism : Dopamine.
- drug therapy : Parkinson Disease.
- etiology : Dyskinesias.
- prevention & control : Dyskinesias.
- Animals, Humans, Pulse Therapy, Drug.
Abstract
Continuous dopaminergic stimulation (CDS) is a treatment strategy hypothesized to avoid or reduce the motor complications of long‐term levodopa therapy, motor fluctuations, and dyskinesia, by preventing or reversing sensitization induced by pulsatile dopaminergic stimulation. The CDS hypothesis is itself based on several hypotheses. First, tonic dopaminergic stimulation is physiological. Second, sensitization is undesirable and should be reversed. Third, reduction of off time and dyskinesia can be induced simultaneously. Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized. © 2006 Movement Disorder Society
Url:
DOI: 10.1002/mds.21060
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001503
- to stream Istex, to step Curation: 001503
- to stream Istex, to step Checkpoint: 001A30
- to stream PubMed, to step Corpus: 002B18
- to stream PubMed, to step Curation: 002B18
- to stream PubMed, to step Checkpoint: 002893
- to stream Ncbi, to step Merge: 001821
- to stream Ncbi, to step Curation: 001821
- to stream Ncbi, to step Checkpoint: 001821
Links to Exploration step
ISTEX:9C5665D2D52950709DB3E36453FB462C55E21011Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9C5665D2D52950709DB3E36453FB462C55E21011</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21060</idno><idno type="url">https://api.istex.fr/document/9C5665D2D52950709DB3E36453FB462C55E21011/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001503</idno><idno type="wicri:Area/Istex/Curation">001503</idno><idno type="wicri:Area/Istex/Checkpoint">001A30</idno><idno type="wicri:doubleKey">0885-3185:2007:Nutt J:continuous:dopaminergic:stimulation</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:16958130</idno><idno type="wicri:Area/PubMed/Corpus">002B18</idno><idno type="wicri:Area/PubMed/Curation">002B18</idno><idno type="wicri:Area/PubMed/Checkpoint">002893</idno><idno type="wicri:Area/Ncbi/Merge">001821</idno><idno type="wicri:Area/Ncbi/Curation">001821</idno><idno type="wicri:Area/Ncbi/Checkpoint">001821</idno><idno type="wicri:doubleKey">0885-3185:2007:Nutt J:continuous:dopaminergic:stimulation</idno><idno type="wicri:Area/Main/Merge">003E44</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Northwest PADRECC, Portland VAMC, and Parkinson Center of Oregon, Oregon Health & Science University, Portland, Oregon</wicri:regionArea><placeName><region type="state">Oregon</region><settlement type="city">Portland</settlement></placeName><orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01">2007-01</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="9">9</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9C5665D2D52950709DB3E36453FB462C55E21011</idno><idno type="DOI">10.1002/mds.21060</idno><idno type="ArticleID">MDS21060</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Dopamine (metabolism)</term><term>Dopamine Agents (administration & dosage)</term><term>Dopamine Agents (adverse effects)</term><term>Dyskinesias (etiology)</term><term>Dyskinesias (prevention & control)</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Parkinson Disease (drug therapy)</term><term>Pulse Therapy, Drug</term><term>continuous dopaminergic stimulation</term><term>levodopa</term><term>randomized clinical trials</term><term>sensitization</term><term>tolerance</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Pulse Therapy, Drug</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Continuous dopaminergic stimulation (CDS) is a treatment strategy hypothesized to avoid or reduce the motor complications of long‐term levodopa therapy, motor fluctuations, and dyskinesia, by preventing or reversing sensitization induced by pulsatile dopaminergic stimulation. The CDS hypothesis is itself based on several hypotheses. First, tonic dopaminergic stimulation is physiological. Second, sensitization is undesirable and should be reversed. Third, reduction of off time and dyskinesia can be induced simultaneously. Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized. © 2006 Movement Disorder Society</div></front></TEI><double doi="10.1002/mds.21060"><ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:9C5665D2D52950709DB3E36453FB462C55E21011</idno><date when="2007" year="2007">2007</date><idno type="doi">10.1002/mds.21060</idno><idno type="url">https://api.istex.fr/document/9C5665D2D52950709DB3E36453FB462C55E21011/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001503</idno><idno type="wicri:Area/Istex/Curation">001503</idno><idno type="wicri:Area/Istex/Checkpoint">001A30</idno><idno type="wicri:doubleKey">0885-3185:2007:Nutt J:continuous:dopaminergic:stimulation</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G." last="Nutt">John G. Nutt</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Northwest PADRECC, Portland VAMC, and Parkinson Center of Oregon, Oregon Health & Science University, Portland, Oregon</wicri:regionArea><placeName><region type="state">Oregon</region><settlement type="city">Portland</settlement></placeName><orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2007-01">2007-01</date><biblScope unit="vol">22</biblScope><biblScope unit="issue">1</biblScope><biblScope unit="page" from="1">1</biblScope><biblScope unit="page" to="9">9</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">9C5665D2D52950709DB3E36453FB462C55E21011</idno><idno type="DOI">10.1002/mds.21060</idno><idno type="ArticleID">MDS21060</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>continuous dopaminergic stimulation</term><term>levodopa</term><term>randomized clinical trials</term><term>sensitization</term><term>tolerance</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Continuous dopaminergic stimulation (CDS) is a treatment strategy hypothesized to avoid or reduce the motor complications of long‐term levodopa therapy, motor fluctuations, and dyskinesia, by preventing or reversing sensitization induced by pulsatile dopaminergic stimulation. The CDS hypothesis is itself based on several hypotheses. First, tonic dopaminergic stimulation is physiological. Second, sensitization is undesirable and should be reversed. Third, reduction of off time and dyskinesia can be induced simultaneously. Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized. © 2006 Movement Disorder Society</div></front></TEI></ISTEX><PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G" last="Nutt">John G. Nutt</name><affiliation wicri:level="4"><nlm:affiliation>Parkinson Center of Oregon, Oregon Health & Science University, Portland, Oregon 97239-3098, USA. nuttj@ohsu.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson Center of Oregon, Oregon Health & Science University, Portland, Oregon 97239-3098</wicri:regionArea><orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName><placeName><settlement type="city">Portland</settlement><region type="state">Oregon</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2007">2007</date><idno type="doi">10.1002/mds.21060</idno><idno type="RBID">pubmed:16958130</idno><idno type="pmid">16958130</idno><idno type="wicri:Area/PubMed/Corpus">002B18</idno><idno type="wicri:Area/PubMed/Curation">002B18</idno><idno type="wicri:Area/PubMed/Checkpoint">002893</idno><idno type="wicri:Area/Ncbi/Merge">001821</idno><idno type="wicri:Area/Ncbi/Curation">001821</idno><idno type="wicri:Area/Ncbi/Checkpoint">001821</idno><idno type="wicri:doubleKey">0885-3185:2007:Nutt J:continuous:dopaminergic:stimulation</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?</title><author><name sortKey="Nutt, John G" sort="Nutt, John G" uniqKey="Nutt J" first="John G" last="Nutt">John G. Nutt</name><affiliation wicri:level="4"><nlm:affiliation>Parkinson Center of Oregon, Oregon Health & Science University, Portland, Oregon 97239-3098, USA. nuttj@ohsu.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson Center of Oregon, Oregon Health & Science University, Portland, Oregon 97239-3098</wicri:regionArea><orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName><placeName><settlement type="city">Portland</settlement><region type="state">Oregon</region></placeName></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="ISSN">0885-3185</idno><imprint><date when="2007" type="published">2007</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term><term>Dopamine (metabolism)</term><term>Dopamine Agents (administration & dosage)</term><term>Dopamine Agents (adverse effects)</term><term>Dyskinesias (etiology)</term><term>Dyskinesias (prevention & control)</term><term>Humans</term><term>Levodopa (administration & dosage)</term><term>Levodopa (adverse effects)</term><term>Parkinson Disease (drug therapy)</term><term>Pulse Therapy, Drug</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Dopamine Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Dopamine</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Dyskinesias</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Animals</term><term>Humans</term><term>Pulse Therapy, Drug</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Continuous dopaminergic stimulation (CDS) is a treatment strategy hypothesized to avoid or reduce the motor complications of long-term levodopa therapy, motor fluctuations, and dyskinesia, by preventing or reversing sensitization induced by pulsatile dopaminergic stimulation. The CDS hypothesis is itself based on several hypotheses. First, tonic dopaminergic stimulation is physiological. Second, sensitization is undesirable and should be reversed. Third, reduction of off time and dyskinesia can be induced simultaneously. Finally, clinical studies substantiate the CDS hypothesis. The evidence for these hypotheses is reviewed, and the need for randomized clinical trials that rigorously test the CDS hypothesis is emphasized.</div></front></TEI></PubMed></double></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003E44 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 003E44 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Merge
|type= RBID
|clé= ISTEX:9C5665D2D52950709DB3E36453FB462C55E21011
|texte= Continuous dopaminergic stimulation: Is it the answer to the motor complications of Levodopa?
}}
| This area was generated with Dilib version V0.6.23. |  |